Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

CSL Limited Posts $1.7b Profit As Dividends Jump

Australia’s largest biotechnology company CSL Limited (ASX: CSL) reported a $1.7 billion profit for 2018, up 28% year over year, and a final unfranked dividend of $US0.93 per share.

“I am pleased to report a strong full year reported profit growth of 29%; slightly ahead of the guidance we provided in May,” CSL CEO Paul Perreault said.

Analysts had been expecting CSL to report a full-year profit of $1.71 billion and full year dividends of $1.66 per share, according to Bloomberg. CSL said its full year dividends total $1.72 per share, up 26%. Based on that, it would appear CSL’s result was slightly ahead of analyst expectations.

Looking under the hood, Mr Perreault said the improved profit was the result of CSL’s patient-focused workforce. CSL creates vaccines and other products to treat, in some instances, life-threatening diseases.

“Our successful launch during the year of HAEGARDA® provides a transformational therapy for patients with Hereditary Angioedema (HAE),” Perreault noted.

“Approval of our immunoglobulin product Privigen® for the US, and Hizentra® for the US and EU, provides patients with a convenient treatment for CIDP, a debilitating peripheral nerve disorder.”

Privigen and Hizentra sales rose 13% and 12%, respectively, in constant currencies. Meanwhile, CSL’s Seqirus subsidiary reported a 55% increase in flu vaccine sales.

“We are proud of our achievements this year, and looking forward to continuing our work in the year ahead,” Perreault said.

Outlook

Despite many years of growth, in 2019 Perreault expects the company to widen its profit margins as higher value products become more prominent features in the sales pipeline. In a bid to limit blood plasma supply constraints, CSL will open between 30 and 35 new collection centres.

With that, CSL’s 2019 profit is expected to grow as much as 14% on its 2018 result to as much as $1.95 billion, subject to market conditions.

So far in 2018 CSL shares have risen from $140 to over $200, according to Google Finance.

Introducing The Australian Investors Podcast

Join The Rask Group’s founder, Owen Raszkiewicz, as he profiles Australia’s best investors, founders, authors and financial thinkers. Download it free on iTunesCastboxSoundCloud or wherever you choose to listen.

itunessoundcloudcastboxdownload

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content